Bendamustine for the treatment of multiple myeloma in first-line and relapsedrefractory settings: A review of clinical trial data

Leukemia and Lymphoma

Volumn 56, Issue 3, 2015, Pages 559-567

  Palumbo, Antonio ^a   Offidani, Massimo ^b   Patriarca, Francesca ^c   Petrucci, Maria Teresa ^d   Cavo, Michele ^e  

^a UNIVERSITY OF TURIN   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bendamustine; clinical data; efficacy; multiple myeloma; tolerability

Indexed keywords

ALKYLATING AGENT; BENDAMUSTINE;

CLINICAL TRIAL (TOPIC); HUMAN; MULTIPLE MYELOMA; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BENDAMUSTINE HYDROCHLORIDE; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL;

EID: 84924709969     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.915545     Document Type: Review

References (45)

1. Pönisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone - a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006;132:205-212.
2. Cai B, Wang S, Huang J, et al. Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. Am J Transl Res 2013;5:36-46.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
4. International Myeloma Foundation: Myeloma Awareness Month 2013 fact-a-day [online]. Available from: http://myeloma.org/ArticlePage.action?articleId=3669
5. Cives M, Ciavarella S, Rizzo FM, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal 2013;25:1108-1117.
6. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-1060.
7. Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcadetrade mark) in the treatment of multiple myeloma. Ther Clin Risk Manag 2006;2:271-279.
8. Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 2011;71:625-649.
9. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008;111:3968-3977.
10. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317-327.
11. Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26:5775-5782.
12. Approved drugs. Carfilzomib [online]. Available from: www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm312945.htm
13. Podar K, Tai YT, Hideshima T, et al. Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs 2009;14:99-127.
14. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet 2009;374:324-339.
15. Moreau P, San Miguel J, Ludwig H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi133-vi137.
16. Napp Pharmaceuticals Limited. Levact 2.5 mg/ml powder for concentrate for solution for infusion. Summary of product characteristics [online]. Available from: www.medicines.org.uk/emc/medicine/23469
17. Cephalon. Treanda (bendamustine hydrochloride). Prescribing information [online]. Available from: www.accessdata.fda.gov/drugsatfda-docs/label/2008/022303lbl.pdf
18. Rummel MJ. Bendamustine in chronic lymphocytic leukemia and refractory lymphoma. Semin Hematol 2008;45:S7-S10.
19. Rummel MJ, Mitrou PS, Hoelzer D. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. Semin Oncol 2002;29:27-32.
20. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-1210.
21. Köster W, Stamatis G, Heider A, et al. Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC). Clin Drug Investig 2004;24:611-618.
22. von Minckwitz G, Chernozemsky I, Sirakova L, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005;16:871-877.
23. Hartmann JT, Mayer F, Schleicher J, et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer 2007;110:861-866.
24. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309-317.
25. Pönisch W, Andrea M, Wagner I, et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 2012;138:1405-1412.
26. Damaj G, Malard F, Hulin C, et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma 2012;53:632-634.
27. Michael M, Bruns I, Bolke E, et al. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010;15:13-19.
28. Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287-1288.
29. Grey-Davies E, Bosworth JL, Boyd KD, et al. Bendamustine, thalidomide and dexamethasone is an eff ective salvage regimen for advanced stage multiple myeloma. Br J Haematol 2012;156:552-555; author reply 555.
30. Pönisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a phase I clinical trial. Br J Haematol 2008;143:191-200.
31. Ramasamy K, Hazel B, Mahmood S, et al. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol 2011;155:632-634.
32. Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012;119:4608-4613.
33. Pönisch W, Heyn S, Beck J, et al. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. Br J Haematol 2013;162:202-209.
34. Pozzi S, Badiali S, Corso A, et al. Bendamustine, low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed multiple myeloma confirms very promising results in a phase I/II study. Blood 2013;122(Suppl. 1): Abstract 3212.
35. Zhang S, Wang X, Chen L, et al. Synergistic activity of bendamustine in combination with doxorubicin and bortezomib in multiple myeloma cells. Blood 2008;112(Suppl. 1): Abstract 5171.
36. Berenson JR, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 2013;160:321-330.
37. Pönisch W, Bourgeois M, Moll B, et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 2013;139:499-508.
38. Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J 2013;3:e162.
39. Fenk R, Michael M, Zohren F, et al. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007;48:2345-2351.
40. Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014;123:985-991.
41. Rodon P, Hulin C, Pegourie B, et al. Bendamustine, bortezomib and dexamethasone (BVD) In elderly patients with multiple myeloma in first relapse: final analysis of the Intergroupe Francophone Du Myelome (IFM) 2009-01 trial. Blood 2013;122(Suppl. 1): Abstract 1971.
42. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
43. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
44. Mark TM, Reid W, Niesvizky R, et al. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2013;19:831-837.
45. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011;118:4519-4529.